Stephen K. Doberstein

2012

In 2012, Stephen K. Doberstein earned a total compensation of $1.1M as Senior Vice President and Chief Scientific Officer at Nektar Therapeutics, a 6% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$260,000
Option Awards$377,540
Salary$433,605
Other$9,613
Total$1,080,758

Doberstein received $433.6K in salary, accounting for 40% of the total pay in 2012.

Doberstein also received $260K in non-equity incentive plan, $377.5K in option awards and $9.6K in other compensation.

Rankings

In 2012, Stephen K. Doberstein's compensation ranked 5,817th out of 11,487 executives tracked by ExecPay. In other words, Doberstein earned more than 49.4% of executives.

ClassificationRankingPercentile
All
5,817
out of 11,487
49th
Division
Manufacturing
2,064
out of 4,252
52nd
Major group
Chemicals And Allied Products
513
out of 1,200
57th
Industry group
Drugs
348
out of 922
62nd
Industry
Pharmaceutical Preparations
273
out of 697
61st
Source: SEC filing on April 30, 2015.

Doberstein's colleagues

We found four more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2012.

2012

Howard Robin

Nektar Therapeutics

Chief Executive Officer

2012

Gil Labrucherie

Nektar Therapeutics

General Counsel

2012

John Nicholson

Nektar Therapeutics

Chief Financial Officer

2012

Rinko Ghosh

Nektar Therapeutics

Senior Vice President and Chief Business Officer

News

You may also like